



## Health Products Regulatory Authority

CERTIFICATE NUMBER: VR18-006/ASR11424

## CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

#### Part 1

Issued following an inspection in accordance with:

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Ireland confirms the following:

The manufacturer: Pfizer Ireland Pharmaceuticals

Site address: Ringaskiddy API Plant, P.O. Box 140, Ringaskiddy, Co. Cork, Ireland

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC transposed in the following national legislation:

Medicinal Products (Control of Manufacture) Regulations 2007 to 2013.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2018-08-17, it is considered that it complies with:

• The principles of GMP for active substances 'referred to in Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

I certify that that this pocument is a true and faithful copy of the original document or of the relevant extracts the do produced to me and which after careful examination I attest

this

7 day of

Hugh McGroddy, Notary Public, 33 Upper Merrion St Dublin 2. Commissioned for Life

HUGH Mc GRODDY 33 Upper Merrion Street Dublin 2 Notary Public for the

County and City of Dublin Commissioned for Life

Online EudraGMDP, Ref key: 52907

Issuance Date: 2019-03-21

Signatory: Mr. Olsin Daly

Page 1 of 16

Slainte, Teach Kevin O'Malley, Ionad Phort an Iarla, Ardán Phort an Iarla, Baile Átha Cliath 2, Éire An tÚdarás Rialála Tair Health Products Reg tory Authority, Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, D02XP77, Ireland

T: +353 1 676 4971

F: +353 1 676 7836

info@hpra.ie

The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

 $<sup>^2</sup>$  Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

<sup>&</sup>lt;sup>3</sup> These requirements fulfil the GMP recommendations of WHO.

1.0	AP (Convention de La	OSTILLE Haye du 5 octol	ore 1961)	
1. Country: Pays/País:	IRELAND		(AC 1501)	
This public docume Le présent acte publi	nt c / El presente docume	IIIO Dúblico	Sec.	
2. has been signed b a été signé par ha sido firmado po	y	Hugh Mc	Groddy *	<u> </u>
3. acting in the capa agissant en qualité quien actúa en calid	de Iad de	Notary Pul	dic	OUS TR
<ol> <li>bears the seal / sta est revêtu du sceau y está revestido del</li> </ol>	/ timbre de	Notary Pub	lic	it lad! fad! viino.
		Certified Certificado	10	thlul copy of the
5. at à/en	Dublin	6. the le / el día	06/06/2019	ich atter/careful
<b>7. by</b> par/por	Department	of Foreign A	fairs and Trade	
. <b>No</b> sous no bajo el número	8713662019		Ni	
Seal / stamp; Sceau / timbre; Sello / timbre;	10. Signature: Signature: Firma:	Sound		

#### Part 2

Manufacture of active substance. Names of substances subject to inspection:

ATORVASTATIN CALCIUM(en)

AZITHROMYCIN DIHYDRATE(en)

CRIZOTINIB(en)

DOFETILIDE( en)

DOXYCYCLINE HYCLATE(en)

DOXYCYCLINE MONOHYDRATE(en)

DESVENLAFAXINE SUCCINATE(en)

ELETRIPTAN HYDROBROMIDE(en)

GABAPENTIN( en)

FESOTERODINE FUMARATE( en)

FLUCONAZOLE(en)

PIROXICAM(en)

PRAZOSIN HYDROCHLORIDE (en)

SILDENAFIL CITRATE(en)

SUNITINIB MALATE( en)

TIGECYCLINE(en)

ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE(en)

AXITINIB( en)

PALBOCICLIB( en)

TAFAMIDIS MEGLUMINE( en)

TAFAMIDIS(en)

VARENICLINE TARTRATE(en)

TOLTERODINE L-TARTRATE(en)

TEMSIROLIMUS( en)

DACOMITINIB( en)

LORLATINIB( en)

PARECOXIB SODIUM(en)

ZIPRASIDONE MESILATE( en)

VORICONAZOLE(en)

ERTUGLIFLOZIN L-PYROGLUTAMIC ACID( en)

TOFACITINIB CITRATE(en)

SERTRALINE HYDROCHLORIDE(en)

GLASDEGIB MALEATE( en)

BOSUTINIB( en)

# 3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

### Active Substance : ATORVASTATIN CALCIUM

3.1	Manufacture of Active Substance by Chemical Synthesis	
	3.1.1 Manufacture of active substance intermediates	
	3.1.2 Manufacture of crude active substance	
- 1	3.1.3 Salt formation / Purification steps:	
	Crystallisation, Isolation, Washing	
3.5	General Finishing Steps	

Online EudraGMDP, Ref key: 52907

Issuance Date: 2019-03-21

Signatory: Mr. Oisin Daly

Page 2 of 16



	3.5.1 Physical processing steps :
	Drying and Milling
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Activ	E Substance: AZITHROMYCIN DIHYDRATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
- 1	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
	Crystallisation, Isolation, Washing
3.5	General Finishing Steps
1	3.5.1 Physical processing steps:
	Drying, Milling, and Sieving
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
1	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
26	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Active	e Substance : CRIZOTINIB
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
	Crystallisation, Isolation, Washing
3.5	General Finishing Steps
	3.5.1 Physical processing steps:
	Drying and Milling
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
3.6	identification or traceability (lot numbering) of the active substance)  Quality Control Testing



3.6.1 Physical / Chemical testing
3.6.2 Microbiological testing excluding sterility testing
e Substance : DOFETILIDE
Manufacture of Active Substance by Chemical Synthesis
3.1.1 Manufacture of active substance intermediates
3.1.2 Manufacture of crude active substance
3.1.3 Salt formation / Purification steps:
Crystallisation, Isolation, Washing
General Finishing Steps
3.5.1 Physical processing steps:
Drying and Milling
3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
which is in direct contact with the substance)
3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
material or container. This also includes any labelling of the material which could be used for
identification or traceability (lot numbering) of the active substance)
Quality Control Testing
3.6.1 Physical / Chemical testing
3.6.2 Microbiological testing excluding sterility testing
Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates
The state of the s
3.1.2 Manufacture of crude active substance
3.1.3 Salt formation / Purification steps:
Crystallisation, Isolation, Washing
General Finishing Steps
General Finishing Steps 3.5.1 Physical processing steps:
General Finishing Steps  3.5.1 Physical processing steps:  Drying and Milling
General Finishing Steps  3.5.1 Physical processing steps: Drying and Milling  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
General Finishing Steps  3.5.1 Physical processing steps:
3.5.1 Physical processing steps: Drying and Milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
General Finishing Steps  3.5.1 Physical processing steps:
3.5.1 Physical processing steps: Drying and Milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
General Finishing Steps  3.5.1 Physical processing steps:
General Finishing Steps  3.5.1 Physical processing steps:
3.5.1 Physical processing steps: Drying and Milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing  3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
General Finishing Steps  3.5.1 Physical processing steps:     Drying and Milling  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing  3.6.1 Physical / Chemical testing  3.6.2 Microbiological testing excluding sterility testing  Substance: DOXYCYCLINE MONOHYDRATE
3.5.1 Physical processing steps: Drying and Milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing  Substance: DOXYCYCLINE MONOHYDRATE  Manufacture of Active Substance by Chemical Synthesis
3.5.1 Physical processing steps: Drying and Milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing  Substance: DOXYCYCLINE MONOHYDRATE  Manufacture of Active Substance by Chemical Synthesis

	Crystallisation, Isolation, Washing		
3.5	General Finishing Steps		
	3.5.1 Physical processing steps :		
	Drying and Milling		
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material		
	which is in direct contact with the substance)		
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging		
	material or container. This also includes any labelling of the material which could be used for		
	identification or traceability (lot numbering) of the active substance)		
3.6	Quality Control Testing		
	3.6.1 Physical / Chemical testing		
	3.6.2 Microbiological testing excluding sterility testing		
Active	Substance: DESVENLAFAXINE SUCCINATE		
3.1	Manufacture of Active Substance by Chemical Synthesis		
	3.1.1 Manufacture of active substance intermediates		
	3.1.2 Manufacture of crude active substance		
- 1	3.1.3 Salt formation / Purification steps:		
	Crystallisation, Isolation, Washing		
3.5	General Finishing Steps		
	3.5.1 Physical processing steps:		
	Drying, Milling, and Sieving		
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material		
	which is in direct contact with the substance)		
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging		
	material or container. This also includes any labelling of the material which could be used for		
	identification or traceability (lot numbering) of the active substance)		
3.6	Quality Control Testing		
	3.6.1 Physical / Chemical testing		
	3.6.2 Microbiological testing excluding sterility testing		
3.1	Substance : ELETRIPTAN HYDROBROMIDE  Manifesture of Active Substance by Chamical Substance		
3.1	Manufacture of Active Substance by Chemical Synthesis		
	3.1.1 Manufacture of active substance intermediates		
	3.1.2 Manufacture of crude active substance		
- 1	3.1.3 Salt formation / Purification steps:		
	Crystallisation, Isolation, Washing		
3.5	General Finishing Steps		
	3.5.1 Physical processing steps:		
	Drying, Milling, and Sieving		
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material		
	which is in direct contact with the substance)		
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging		
	material or container. This also includes any labelling of the material which could be used for		



3.6	Quality Control Testing  3.6.1 Physical / Chemical testing
	2.6.1 Physical / Chamical testing
	·
	3.6.2 Microbiological testing excluding sterility testing
Active	e Substance : GABAPENTIN
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
_ 1	3.1.3 Salt formation / Purification steps:
	Crystallisation, Isolation, Washing
3.5	General Finishing Steps
	3.5.1 Physical processing steps:
	Drying
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
3.6	identification or traceability (lot numbering) of the active substance)  Quality Control Testing
3.0	
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Active	e Substance : FESOTERODINE FUMARATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
	Crystallisation, Isolation, Washing
3.5	General Finishing Steps
	3.5.1 Physical processing steps:
	Drying, Milling, and Sieving
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
4	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
	e Substance : FLUCONAZOLE
Active	Substance . FLUCONAZULE



	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
	Crystallisation, Isolation, Washing
3.5	General Finishing Steps
	3.5.1 Physical processing steps :
- 1	Drying and Milling
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
A ative	e Substance : PIROXICAM
3.1	Manufacture of Active Substance by Chemical Synthesis
(EUFFL)	3.1.1 Manufacture of active substance intermediates
1	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
- 1	Crystallisation, Isolation, Washing
3.5	General Finishing Steps
	3.5.1 Physical processing steps :
	Drying and Milling
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Active	
Active	3.6.2 Microbiological testing excluding sterility testing
	3.6.2 Microbiological testing excluding sterility testing  e Substance : PRAZOSIN HYDROCHLORIDE
	3.6.2 Microbiological testing excluding sterility testing  e Substance: PRAZOSIN HYDROCHLORIDE  Manufacture of Active Substance by Chemical Synthesis
	3.6.2 Microbiological testing excluding sterility testing  E Substance: PRAZOSIN HYDROCHLORIDE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates
	3.6.2 Microbiological testing excluding sterility testing  e Substance: PRAZOSIN HYDROCHLORIDE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates  3.1.2 Manufacture of crude active substance
	3.6.2 Microbiological testing excluding sterility testing  e Substance: PRAZOSIN HYDROCHLORIDE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates  3.1.2 Manufacture of crude active substance  3.1.3 Salt formation / Purification steps:
3.1	3.6.2 Microbiological testing excluding sterility testing  Substance: PRAZOSIN HYDROCHLORIDE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates  3.1.2 Manufacture of crude active substance  3.1.3 Salt formation / Purification steps: Crystallisation, Isolation, Washing  General Finishing Steps  3.5.1 Physical processing steps:
3.1	3.6.2 Microbiological testing excluding sterility testing  Substance: PRAZOSIN HYDROCHLORIDE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates  3.1.2 Manufacture of crude active substance  3.1.3 Salt formation / Purification steps:  Crystallisation, Isolation, Washing  General Finishing Steps





	which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for
3.6	identification or traceability (lot numbering) of the active substance)  Quality Control Testing
	<ul> <li>3.6.1 Physical / Chemical testing</li> <li>3.6.2 Microbiological testing excluding sterility testing</li> </ul>
Activo	e Substance : SILDENAFIL CITRATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	<ul> <li>3.1.1 Manufacture of active substance intermediates</li> <li>3.1.2 Manufacture of crude active substance</li> <li>3.1.3 Salt formation / Purification steps :</li></ul>
3.5	General Finishing Steps
	<ul> <li>3.5.1 Physical processing steps:     Drying, Milling, and Sieving</li> <li>3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)</li> <li>3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)</li> </ul>
3.6	Quality Control Testing
AND PARTY OF THE PARTY OF	
Active	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing  e. Substance: SUNITINIB MALATE.
Active	3.6.2 Microbiological testing excluding sterility testing e Substance : SUNITINIB MALATE
3.1	3.6.2 Microbiological testing excluding sterility testing  e Substance: SUNITINIB MALATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates  3.1.2 Manufacture of crude active substance  3.1.3 Salt formation / Purification steps:  Crystallisation, Isolation, Washing
	3.6.2 Microbiological testing excluding sterility testing  e Substance : SUNITINIB MALATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates  3.1.2 Manufacture of crude active substance  3.1.3 Salt formation / Purification steps :  Crystallisation, Isolation, Washing  General Finishing Steps
3.1	a.6.2 Microbiological testing excluding sterility testing  e Substance : SUNITINIB MALATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates  3.1.2 Manufacture of crude active substance  3.1.3 Salt formation / Purification steps :
3.1	a.6.2 Microbiological testing excluding sterility testing  Bubstance: SUNITINIB MALATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Crystallisation, Isolation, Washing  General Finishing Steps  3.5.1 Physical processing steps: Drying and Sieving  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for



3.1	Manufacture of Active Substance by Chemical Synthesis
100	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
	Crystallisation, Isolation, Washing
3.5	General Finishing Steps
	3.5.1 Physical processing steps:
	Drying
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
- 1	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
1	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
3.1	Manufacture of Active Substance by Chemical Synthesis
TOTIVE	Substance: ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE
3.1	Manufacture of Active Substance by Chemical Synthesis
3.1	Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates
3.1	
3.1	3.1.1 Manufacture of active substance intermediates
3.1	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance
3.1	<ul> <li>3.1.1 Manufacture of active substance intermediates</li> <li>3.1.2 Manufacture of crude active substance</li> <li>3.1.3 Salt formation / Purification steps :</li> </ul>
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5 3.6	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5 3.6	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5 3.6	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5 3.6	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:

ignatory. M

EddraGMDI



3.6	<ul> <li>3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)</li> <li>3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)</li> <li>Quality Control Testing</li> <li>3.6.1 Physical / Chemical testing</li> </ul>
	which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
	which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	which is in direct contact with the substance)
	Milling, Drying  3.5.2. Primary Packaging (enclosing / scaling the active substance within a neckaging metarial)
	3.5.1 Physical processing steps:
3.5	General Finishing Steps
	Crystallised, Washed, Isolated, Filtered
	3.1.3 Salt formation / Purification steps :
	3.1.2 Manufacture of crude active substance
	3.1.1 Manufacture of active substance intermediates
3.1	Manufacture of Active Substance by Chemical Synthesis
\ ctiv	e Substance : TAFAMIDIS MEGLUMINE
	3.6.1 Physical / Chemical testing
3.6	Quality Control Testing
	material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
	which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	Drying
	3.5.1 Physical processing steps:
3.5	General Finishing Steps
	Crystallisation
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
	<ul><li>3.1.1 Manufacture of active substance intermediates</li><li>3.1.2 Manufacture of crude active substance</li></ul>
3.1	Manufacture of Active Substance by Chemical Synthesis
	e Substance : PALBOCICLIB
	J.O.1 Physical Colembia testing
3.0	3.6.1 Physical / Chemical testing
3.6	identification or traceability (lot numbering) of the active substance)  Quality Control Testing
	material or container. This also includes any labelling of the material which could be used for
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	which is in direct contact with the substance)
	Milling, Drying  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	AUGURA LINUAR



Page 10 of 16

3.1	Manufacture of Active Substance by Chemical Synthesis
	A STATE OF THE STA
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
	Crystallisation, Washed, Isolated, Filtered
3.5	General Finishing Steps
CAL SOL	3.5.1 Physical processing steps:
	Milling, Drying
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
i	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
ĺ	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
F16.5537	3.6.1 Physical / Chemical testing
3.1	e Substance: VARENICLINE TARTRATE  Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
	Crystallisation, Filtered, Washed
3.5	
3,5	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps:
3.5	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps:
3.5	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps: Drying, Milling  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
3.5	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps: Drying, Milling  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.5	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps: Drying, Milling  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
3.5	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps: Drying, Milling  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for
	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps: Drying, Milling  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.5	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps: Drying, Milling  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing
	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps: Drying, Milling  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps:
3.6	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps:     Drying, Milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing  3.6.1 Physical / Chemical testing  We Substance: TOLTERODINE L-TARTRATE  Manufacture of Active Substance by Chemical Synthesis
3.6	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps:     Drying, Milling  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing  3.6.1 Physical / Chemical testing  We Substance: TOLTERODINE L-TARTRATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates
3.6	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps:     Drying, Milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing  3.6.1 Physical / Chemical testing  We Substance: TOLTERODINE L-TARTRATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance
3.6	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps:     Drying, Milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)  Quality Control Testing  3.6.1 Physical / Chemical testing  We Substance: TOLTERODINE L-TARTRATE  Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.6	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps:
3.6	Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps:



	Drying, Milling
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
20	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	e Substance : TEMSIROLIMUS
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
	Crystallisation, Filtered, Washed
3.5	General Finishing Steps
	3.5.1 Physical processing steps:
	Drying Co. S. C. Driving
- 1	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
- 1	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
12000	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
	Substance : DACOMITINIB
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
1	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
3.5	Crystallisation, Filtered, Washed  General Finishing Steps
La Library	3.5.1 Physical processing steps:
	Drying, Milling
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing



3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
	Crystallisation, Isolation, Washing
3.5	General Finishing Steps
	3.5.1 Physical processing steps:
	Drying, Milling
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active	e Substance : PARECOXIB SODIUM
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	a to M. C. town of amide cative substance
1	3.1.2 Manufacture of crude active substance
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
	3.1.3 Salt formation / Purification steps:
3.5	
3.5	3.1.3 Salt formation / Purification steps:  Crystallisation, Filtered, Washed
3.5	3.1.3 Salt formation / Purification steps: Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps: Drying
3.5	3.1.3 Salt formation / Purification steps: Crystallisation, Filtered, Washed  General Finishing Steps  3.5.1 Physical processing steps: Drying
3.5	3.1.3 Salt formation / Purification steps:
3.5	3.1.3 Salt formation / Purification steps:
3.5	3.1.3 Salt formation / Purification steps:
3.5	3.1.3 Salt formation / Purification steps:
3.5	3.1.3 Salt formation / Purification steps:
	3.1.3 Salt formation / Purification steps:
	3.1.3 Salt formation / Purification steps:
3.6	3.1.3 Salt formation / Purification steps:
3.6	3.1.3 Salt formation / Purification steps:
3.6	3.1.3 Salt formation / Purification steps:
3.6	3.1.3 Salt formation / Purification steps:
3.6	3.1.3 Salt formation / Purification steps:
3.6	3.1.3 Salt formation / Purification steps:



	3.5.1 Physical processing steps:
	Drying, Milling, and Sieving
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
21	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Active	e Substance : VORICONAZOLE
3.1	Manufacture of Active Substance by Chemical Synthesis
PORTEN BY	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
	Crystallisation, Isolation, Washing
3.5	General Finishing Steps
	3.5.1 Physical processing steps:
	Drying, Milling, and Sieving
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	, Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Active	e Substance : ERTUGLIFLOZIN L-PYROGLUTAMIC ACID
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
	Crystallisation, Isolation, Washing
3.5	Crystallisation, Isolation, Washing General Finishing Steps
3.5	Crystallisation, Isolation, Washing  General Finishing Steps  3.5.1 Physical processing steps:
3.5	Crystallisation, Isolation, Washing  General Finishing Steps  3.5.1 Physical processing steps:  Milling, Drying
3.5	Crystallisation, Isolation, Washing  General Finishing Steps  3.5.1 Physical processing steps: Milling, Drying  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
3.5	Crystallisation, Isolation, Washing  General Finishing Steps  3.5.1 Physical processing steps:     Milling, Drying  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.5	Crystallisation, Isolation, Washing  General Finishing Steps  3.5.1 Physical processing steps:     Milling, Drying  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
3.5	Crystallisation, Isolation, Washing  General Finishing Steps  3.5.1 Physical processing steps:     Milling, Drying  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for
3.5	Crystallisation, Isolation, Washing  General Finishing Steps  3.5.1 Physical processing steps:     Milling, Drying  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging

	C. L. C. TOTAL CUTTO UP. CUTTO LITT
00/11/2	e Substance : TOFACITINIB CITRATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
	Crystallisation, Isolation, Washing
3.5	General Finishing Steps
	3.5.1 Physical processing steps:  Drying
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
- 1	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
3.6	identification or traceability (lot numbering) of the active substance)  Quality Control Testing
3.0	
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
3.1	e Substance : SERTRALINE HYDROCHLORIDE  Manufacture of Active Substance by Chemical Synthesis
15 PENA	
	3.1.1 Manufacture of active substance intermediates
	<ul><li>3.1.1 Manufacture of active substance intermediates</li><li>3.1.2 Manufacture of crude active substance</li></ul>
	3.1.2 Manufacture of crude active substance
3.5	<ul><li>3.1.2 Manufacture of crude active substance</li><li>3.1.3 Salt formation / Purification steps :</li></ul>
3.5	<ul> <li>3.1.2 Manufacture of crude active substance</li> <li>3.1.3 Salt formation / Purification steps :</li></ul>
3.5	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:  Crystallisation, Isolation, Washing  General Finishing Steps
3.5	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5	<ul> <li>3.1.2 Manufacture of crude active substance</li> <li>3.1.3 Salt formation / Purification steps:</li></ul>
3.5	<ul> <li>3.1.2 Manufacture of crude active substance</li> <li>3.1.3 Salt formation / Purification steps:</li></ul>
3.5	<ul> <li>3.1.2 Manufacture of crude active substance</li> <li>3.1.3 Salt formation / Purification steps:</li></ul>
3.5	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.6	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.6	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.6	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.6	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.6	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.6	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:



	3.5.1 Physical processing steps :
	Drying, Milling
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active	e Substance : BOSUTINIB
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

2019-03-21

Name and signature of the authorised person of the Competent Authority of Ireland

Mr. Oisin Daly

Health Products Regulatory Authority

Tel: +353 31 6764971

Fax

